US 11,938,166 B2
Methods and compositions for treating mucosal tissue disorders
Roland R. Arnold, Chapel Hill, NC (US); and David C. Henke, Chapel Hill, NC (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,096.
Application 17/348,096 is a continuation of application No. 16/529,204, filed on Aug. 1, 2019, granted, now 11,058,743.
Application 16/529,204 is a continuation of application No. 15/040,731, filed on Feb. 10, 2016, granted, now 10,406,200, issued on Sep. 10, 2019.
Application 15/040,731 is a continuation of application No. 14/446,192, filed on Jul. 29, 2014, granted, now 9,308,234, issued on Apr. 12, 2016.
Application 14/446,192 is a continuation of application No. PCT/US2013/067307, filed on Oct. 29, 2013.
Claims priority of provisional application 61/719,804, filed on Oct. 29, 2012.
Prior Publication US 2022/0143129 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/06 (2006.01); A01N 1/02 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 31/375 (2006.01); A61K 33/00 (2006.01); A61K 33/04 (2006.01); A61K 33/10 (2006.01); A61K 38/40 (2006.01); A61K 38/44 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/063 (2013.01) [A01N 1/0226 (2013.01); A61K 9/0031 (2013.01); A61K 9/0034 (2013.01); A61K 9/006 (2013.01); A61K 9/0073 (2013.01); A61K 9/0075 (2013.01); A61K 9/008 (2013.01); A61K 31/198 (2013.01); A61K 31/375 (2013.01); A61K 33/00 (2013.01); A61K 33/04 (2013.01); A61K 33/10 (2013.01); A61K 38/40 (2013.01); A61K 38/443 (2013.01); A61K 45/06 (2013.01); C12Y 101/03004 (2013.01); C12Y 111/01007 (2013.01); C12Y 302/01011 (2013.01); C12Y 302/01017 (2013.01); C12Y 302/01059 (2013.01)] 36 Claims
 
1. A method for reducing the onset and/or progression of bacterial growth in a subject's airway, comprising prophylactically administering by inhalation to the airway of the subject an effective amount of a composition comprising:
a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
b) an organic acid or a pharmaceutically-acceptable salt of an organic acid; and
c) a carrier,
wherein the subject suffers from a pulmonary or airway disorder or disease selected from the group consisting of an inflammatory lung disease and/or infection of the lung, inflammation and/or infection associated with lung transplantation, acute lung rejection, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and any combination thereof.